Torrent Pharmaceuticals is gearing up to launch both oral and injectable versions of semaglutide, the weight loss drug, following the expiration of Novo Nordisk's patent. The company is currently in Phase 3 clinical trials for oral products and has partnered for injectables, anticipating a launch within the next 1-2 years.